- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02229773
Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 1464 (Tablet) in Hyperlipemic Healthy Male Subjects
August 28, 2014 updated by: Boehringer Ingelheim
Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability After Multiple Oral Doses of 0.25 mg, 0.5 mg and 1 mg o.d. BIBB 1464 (Tablet) or Pravastatin 20 mg Over 2 Weeks in Hyperlipemic Healthy Male Subjects (Parallel Group Comparison, Randomized, Placebo Controlled, Partly Double Blind [Pravastatin Open])
Lipid lowering effect, investigation of pharmacodynamics (inhibition of oxidosqualene cyclase, monoepoxysqualene (MES) as marker), safety / tolerability and preliminary pharmacokinetics
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy male Caucasian subjects as determined by results of screening
- Written informed consent in accordance with GCP and local legislation given
- Age >= 18 and <= 65 years
- Broca >= - 20% and <= + 30%
- LDL-cholesterol level >= 3.3 mmol/L at pre-screening and at the two screening visits
Exclusion Criteria:
- Any finding of the medical examination. (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal (including thyroid) disorder
- Surgery of the gastro-intestinal tract (except appendectomy)
- Disease of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- History or orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections
- History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged the investigator
- Intake of drugs with a long half-life (> 24 hours) (<= 1 month prior to administration or during the trial)
- Use of any drugs which might influence the result of the trial (<= 10 days prior to administration or during the trial)
- Participation in another trial with an investigational drug (<= 2 month prior to administration or during the trial)
- Smoker (> 10 cigarettes or > 3 cigars or >3 pipes/day)
- Inability to refrain from smoking during the period of the study
- Alcohol abuse (>60/g/day)
- Drug abuse
- Blood donation (>400ml <=1 month prior to administration)
- Excessive physical activities (<=5 days prior to administration)
- Any laboratory value outside the normal range of clinical relevance
- LDL - cholesterol screening measurements day -1 and day -7 the different between these two values exceed 12% of the higher dose
- subjects who are vegetarian
Eye-lens
- Cataract extraction in one or both eyes deemed likely within 2 years ("senile", non-idiopathic will not automatically exclude patients from participation)
- Lens Opacities Classification System (LOCS) III grade >3.0 (for nuclear opalescence or cortical grad) >0.5 (for posterior sub capsular grad)
- Log MAR Bailey-Lovie visual acuity >0.5
- Corneal or conjunctival problems which would preclude lens photography
- Shallow anterior chamber with risk of angle-closure glaucoma
- Pupil will not dilate to at least 6 mm
- Visually significant fundus pathology in clinician's judgment
- Amblyopia, optic nerve disease, iritis, history of eye surgery, argon or YAG laser, major eye trauma, extended use (daily for >3 month) of ocular or systemic corticosteroid treatment , use of anticoagulants, or glaucoma therapy, or participation in another clinical trial investigation an anti-cataract or cataractogenic formulation within the last year
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
|
Active Comparator: Pravastatin
|
|
Experimental: BIBB 1464 MS low dose
|
|
Experimental: BIBB 1464 MS medium dose
|
|
Experimental: BIBB 1464 MS high dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage change of LDL plasma cholesterol
Time Frame: baseline, 2 weeks
|
baseline, 2 weeks
|
Percentage change of total plasma cholesterol
Time Frame: baseline, 2 weeks
|
baseline, 2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage change in lipid profile
Time Frame: baseline, 1 week
|
baseline, 1 week
|
Number of patients with adverse events
Time Frame: Up to day 42
|
Up to day 42
|
Number of patients with clinical significant findings in eye lens opacification
Time Frame: Up to day 42
|
Up to day 42
|
Number of patients with clinical significant findings in laboratory parameters
Time Frame: Up to day 28
|
Up to day 28
|
Number of patients with clinical significant findings in electrocardiogram (ECG)
Time Frame: Up to day 28
|
Up to day 28
|
Number of patients with clinical significant findings in physical examination
Time Frame: Up to day 28
|
Up to day 28
|
Number of patients with clinical significant findings in vital signs
Time Frame: Up to day 15
|
Up to day 15
|
Investigator assessed tolerability on a 4 point scale
Time Frame: day 42
|
day 42
|
Amount of drug excreted in urine
Time Frame: Up to day 15
|
Up to day 15
|
Drug plasma concentration
Time Frame: Up to day 28
|
Up to day 28
|
Monoepoxysqualene (MES) plasma concentration
Time Frame: Up to day 28
|
Up to day 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2000
Primary Completion (Actual)
May 1, 2000
Study Registration Dates
First Submitted
August 28, 2014
First Submitted That Met QC Criteria
August 28, 2014
First Posted (Estimate)
September 1, 2014
Study Record Updates
Last Update Posted (Estimate)
September 1, 2014
Last Update Submitted That Met QC Criteria
August 28, 2014
Last Verified
August 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1178.2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States